

ASX RELEASE**Non-cash impairment of intangible assets & confirmation of FY24 guidance**

1st August 2024 – Global analytical science and device company Trajan Group Holdings Limited (ASX: TRJ) (Trajan or the Company) announced it has assessed the carrying value of the Company's assets for impairment at 30 June 2024 as part of its financial results preparation.

An impairment assessment was undertaken in accordance with the relevant accounting standards with the Company expecting, subject to final audit review, to recognise a \$26.7M non-cash impairment of intangible and financial assets of which the majority relates to Neoteryx goodwill and intangibles (\$25.0M). While the requirement to write down assets predominantly related to microsampling, the Company has seen strong order demand trends in this area with a 29.8% increase in H2 (over H1) and performance remains aligned with the guidance provided in May. The remaining \$1.7M asset write down relates to the carrying value of other microsampling related assets.

The impairment will be recorded in the Company's Full Year 2024 Financial Results, due to be released on 29th August 2024, and are non-cash in nature.

As a result of the Neoteryx impairment, the Company had a technical breach of a financial covenant requiring a minimum shareholders' equity amount at 30 June 2024. This is now resolved, with no implications to debt arrangements.

The Company confirms its performance remains aligned with the financial guidance ranges provided in its May update, including Net Revenue and Core nEBITDA.

Authorised for ASX release by the Board of Trajan Group Holdings Limited.

END

Contact:**Investors**

Rebecca Wilson

Marie Krstic

investorrelations@trajanscimed.com

Media

Ana Luiza Graça Harrop

Amy Miller

media@trajanscimed.com



About Trajan

Trajan is a global developer and manufacturer of analytical and life sciences products and devices founded to enable science that benefits people by enriching personal health through scientific tools and solutions. These products and solutions are used in the analysis of biological, food, and environmental samples. Trajan has a portfolio and pipeline of new technologies which support the move towards decentralised, personalised data-based healthcare.

Trajan is a global organisation of more than 600 people, with seven manufacturing sites across the US, Australia, Europe and Malaysia, and operations in Australia, the US, Asia, and Europe.